Tokyo, Japan – February 15, 2025 – Abrax Japan, is pleased to announce the appointment of Dr. William Chin, MD and Dr. Zoltan (Zolt) Arany, MD, PhD as the newest members of its Scientific Advisory Board. These esteemed leaders in medicine and science bring a wealth of expertise and insight that will support Abrax Japan’s mission to advance groundbreaking therapies in metabolic and cardiovascular health.
Dr. William Chin is an Emeritus Professor of Medicine at Harvard Medical School and a former Senior Vice President of Discovery Research at Eli Lilly. A renowned physician-scientist, Dr. Chin specializes in molecular genetics and endocrinology, having made significant contributions to scientific advancements through his extensive publications and patents. With a career spanning both academia and industry, Dr. Chin exemplifies a commitment to innovation and the advancement of medical science.
Dr. Zoltan Arany is the Samuel Bellet Professor of Cardiology and Director of the Cardiovascular Metabolism Program at the Perelman School of Medicine at the University of Pennsylvania. A summa cum laude graduate of Harvard College, Dr. Arany earned his MD from Harvard Medical School and his PhD from the Harvard Graduate School of Arts and Sciences, where he trained under Dr. David Livingston. Dr. Arany completed his internal medicine residency at Massachusetts General Hospital, followed by fellowship training in cardiology at Brigham and Women’s Hospital, and a post-doctoral research fellowship at the Dana-Farber Cancer Institute under Dr. Bruce Spiegelman.
Since joining the University of Pennsylvania in 2014, Dr. Arany has focused his research on the metabolic mechanisms underlying cardiovascular disease. His laboratory takes a multidisciplinary approach, bridging molecular biology, omics technologies, model organisms, and clinical studies. Recent areas of focus include the metabolic shifts in human heart failure, vascular contributions to diabetes, and maternal cardiac disease during and after pregnancy. In addition to his research, Dr. Arany is a dedicated clinician, educator, and mentor, currently serving as Chair of the Cellular Biology, Physiology, and Metabolism Graduate Group.
Jo Narita, CEO of Abrax Japan, expressed enthusiasm about the appointments, saying, “We are incredibly excited to welcome both Bill and Zolt to our team. Their unparalleled expertise in metabolic syndromes and cardiovascular research will be instrumental as Abrax advances into the clinical stages of development.”
With these new appointments, Abrax Japan strengthens its commitment to pioneering therapies that address critical unmet needs in metabolic and cardiovascular health.
If you have any questions or comments or would like to request an interview, please contact Abrax Japan, and our representative will get in touch with you promptly.
